MedWatch

Novo-owned Xellia prepares for launch of own products: "It's been a long journey"

Denmark's Xellia Pharmaceuticals will soon transition from being a supplier of anti-infective drugs to a pharma company with its own products on the market. According to the CEO, it has been an "interesting journey" that began when Novo Holdings acquired the company in 2013.

Copenhagen-based Xellia Pharmaceuticals is about to complete a transformation that began when Novo Holdings acquired the company in 2013 for USD 700 million.

"With Novo we took a long hard look at the business, and it led to a complete change of strategy in 2014, when we reset everything for a different journey," explains Carl-Åke Carlsson, CEO of Xellia Pharmaceuticals.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Nye insulintilskud bekymrer Diabetesforeningen

Diabetesforeningen er utilfredse med Medicintilskudsnævnets indstilling til en revurdering af tilskud for diabetesmidler, som patientforeningen anser som en spareøvelse uden hensyntagen til patienterne.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier